- Conditions
- Pancreatic Cancer
- Interventions
- PEGPH20, Cetuximab, DW & DCE-MRI, blood draws
- Drug · Device · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 79
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain Injuries, Cerebrovascular Disorders
- Interventions
- DCE MRI of the brain
- Procedure
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast- Enhanced (DCE) MRI
- Diagnostic Test
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- Pazopanib Hydrochloride, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Gout
- Interventions
- Pegloticase, Azathioprine
- Biological · Drug
- Lead sponsor
- Ampel BioSolutions, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Wheaton, Maryland + 8 more
- Conditions
- Prostate Cancer
- Interventions
- multi-parametric MRI(MP-MRI), dynamic contrast-enhanced MRI (DCE), biopsy
- Device · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
- Interventions
- MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Cancer
- Interventions
- Bevacizumab, Temsirolimus, Additional Blood Drawn, Biopsy, DCE-MRI Scan
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease
- Interventions
- GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI
- Device · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 20 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- sorafenib tosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, computed tomography, dynamic contrast-enhanced magnetic resonance imaging
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tumors Metastatic to Brain, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- diffusion-weighted magnetic resonance imaging, chemical exchange saturation transfer magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, dynamic susceptibility contrast-enhanced magnetic resonance imaging
- Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Prostate Cancer
- Interventions
- 3-Tesla magnetic resonance imaging (3T MRI), diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging
- Procedure
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- Male only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Adult Brain Glioblastoma
- Interventions
- Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Interventions
- 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, MRI-Based Angiogram
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadolinium-Chelate, Gemcitabine, Irinotecan, Leucovorin Calcium, Nab-paclitaxel, Oxaliplatin, Point-of-care portable perfusion phantom (P4)
- Procedure · Drug · Device
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Soft Tissue Sarcoma
- Interventions
- MRI-DCE
- Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pancreatic Cancer
- Interventions
- Point-of-care Portable Perfusion Phantom, P4
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Nashville, Tennessee
- Conditions
- Traumatic Brain Injury
- Interventions
- Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
- Drug · Device · Other + 1 more
- Lead sponsor
- Uniformed Services University of the Health Sciences
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- cediranib maleate, laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, pharmacological study
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Ependymoma, Refractory Medulloblastoma
- Interventions
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-enhanced MR Perfusion, Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging, Magnetic Resonance Spectroscopic Imaging, Pembrolizumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
- Biological · Drug · Other + 2 more
- Lead sponsor
- John Hays
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more
- Conditions
- BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Interventions
- 18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Positron Emission Tomography
- Other · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota